Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study

14 May 2013

Abstract excerpt

Several cytogenetic abnormalities are associated with poor outcomes in multiple myeloma (MM). We prospectively analyzed the impact of cytogenetic abnormalities on outcomes during the phase 2 PX-171-003-A1 study of single-agent carfilzomib for relapsed and refractory MM. In the response-evaluable population (257/266), fluorescence in situ hybridization (FISH)/conventional cytogenetic profiles were available for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyloidosis: Diagnosis, Treatment, Outcomes
Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23670297
DOI: 10.1038/leu.2013.152

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 studyPMID 23670297Read ↗

Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myelomaSemantic proximity Read ↗

Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high‐risk cytogenetics: IKEMA subgroup analysisSemantic proximity Read ↗

Clinical implications of cytogenetic and molecular aberrations in multiple myelomaSemantic proximity Read ↗

Impact of High-Risk Cytogenetics and Achievement of Molecular Remission on Long-Term Freedom from Disease after Autologous–Allogeneic Tandem Transplantation in Patients with Multiple MyelomaSemantic proximity Read ↗

Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment responseSemantic proximity Read ↗

Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalitiesSemantic proximity Read ↗

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du MyelomeSemantic proximity Read ↗

A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy.Semantic proximity Read ↗

Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trialSemantic proximity Read ↗

Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myelomaSemantic proximity Read ↗

Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogeneticsSemantic proximity Read ↗

Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.